Inflamation, Obesity & Overweight, Oxidative Stress, Prediabetes
Conditions
Keywords
FOOD BIOACTIVES, FOOD BIOACTIVE COMPOUNDS, OLIVE PRODUCTS, BILBERRY PRODUCTS, OLEA EUROPEA L., BILBERRY, VACCINUM MYRTILLOUS L., GUT MICROBIOME, MICROBIOME MAPPING, IN VITRO, IN SILICO, BIOACTIVE COMPOUNDS, METABOLISM
Brief summary
Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver/intestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network "BioTransform," two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2. Bilberry /blueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.
Interventions
Through this pilot clinical study, the possible change of inflammatory and oxidative stress biomarkers in prediabetic, overweigh/ obese people will be observed. Blood, urine and stool samples will be collected, while weight mangment will also be controlled.
Sponsors
Study design
Eligibility
Inclusion criteria
* 30-50 years old, * BMI\> 25 kg/m2 * prediabetic stage * hsCRP\> 2mg/ L * HbA1c 5,7-6,4% * Impaired fasting glucose (IFG) * Caucasian
Exclusion criteria
* No signed informed consent * Supplementation or probiotic usage in the past 8 weeks * Chronic gastrointestinal, inflammatory or metabolic diseases * Alcohol misuse * Pregnancy or breastfeeding * Acute infection during the past month
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in inflammatory and oxidative stress markers | 14 weeks | The changes in the inflammatory and oxidative stress markers will be assessed through blood samples and the biomarkers: hsCRP, IL-6, TNF-a, total antioxidant capacity, ratio glutathione/ oxidiced glutathion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lipid profile | 14 weeks | Blood samples: TCHOL, HDL, LDL, TG |
| Inflammatory profile | 14 weeks | Blood samples: ICAM-1, VCAM-1, CRP-C |
| Anthropometric profile | 14 weeks | Body measurements: BMI and body weight changes |
| Metabolic profile | 14 weeks | Urine and plasma samples: metabolite profile in urine and plasma |
| Microbiome profile | 14 weeks | Stool samples: microbiome diversity, microbiome composition changes, and microbiome functionality |
Countries
Greece